Market Place
Sourcing Support
Veracyte`s Test Predicts Chemo Benefit In Metastatic Prostate Cancer
15 Sep 2024 //
BUSINESSWIRE
Veracyte Announces Second Quarter 2024 Financial Results
06 Aug 2024 //
BUSINESSWIRE
Veracyte`s Afirma GRID Suggests Thyroid Tumor Molecular Testing Prognosis
03 Jun 2024 //
BUSINESSWIRE
Veracyte to Participate in Upcoming Investor Conferences
15 May 2024 //
BUSINESSWIRE
Veracyte Announces First Quarter 2024 Financial Results
07 May 2024 //
BUSINESSWIRE
Veracyte’s Prostate Test Receives Evidence-Level Rating Among Molecular Tests
27 Feb 2024 //
PRESS RELEASE
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
22 Feb 2024 //
PRESS RELEASE
Veracyte to Participate in the Raymond James 45th Annual Investors Conference
21 Feb 2024 //
PRESS RELEASE
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results
08 Feb 2024 //
PRESS RELEASE
Veracyte Completes Acquisition of C2i Genomics
06 Feb 2024 //
BUSINESSWIRE
Veracyte to buy C2i Genomics for up to $95M, includes $70M upfront
08 Jan 2024 //
ENDPTS
Veracyte Announces In Vitro Diagnostic Agreement with Illumina
07 Nov 2023 //
BUSINESSWIRE
Veracyte Announces Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Veracyte Announces SITC 2023 Presentations
27 Oct 2023 //
BUSINESSWIRE
Veracyte Announces Novel Afirma-Based Findings of Thyroid Cancer to Be Presented
21 Sep 2023 //
BUSINESSWIRE
Veracyte Announces Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility
30 Apr 2023 //
BUSINESSWIRE
Veracyte Announces Seven Abstracts for Decipher Urologic Cancer Tests
12 Apr 2023 //
BUSINESSWIRE
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023
15 Mar 2023 //
BUSINESSWIRE
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
22 Feb 2023 //
BUSINESSWIRE
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results
06 Feb 2023 //
BUSINESSWIRE
Veracyte Announces Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
01 Feb 2023 //
BUSINESSWIRE
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented
01 Feb 2023 //
BUSINESSWIRE
Data Published in JCEM Demonstrate Performance of Veracyte’s Afirma GSC
15 Dec 2022 //
BUSINESSWIRE
Veracyte Announces Third Quarter 2022 Financial Results
02 Nov 2022 //
BUSINESSWIRE
JNCI Demonstrate Veracyte’s DPGC May Improve Identification of Prostate Cancer
22 Sep 2022 //
BUSINESSWIRE
Veracyte Names John Leite as General Manager of Pulmonology & Market Access
13 Sep 2022 //
BUSINESSWIRE
Veracyte’s Decipher Classifier Help Inform Treatment Decisions in Men
11 Sep 2022 //
BUSINESSWIRE
Veracyte to Participate in Morgan Stanley Annual Global Healthcare Conference
01 Sep 2022 //
BUSINESSWIRE
Nature Suggest Pre-Treatment TME Can Impact Response for CAR T-Cell Therapy
29 Aug 2022 //
BUSINESSWIRE
Veracyte Announces Second Quarter 2022 Financial Results
02 Aug 2022 //
BUSINESSWIRE
New Data Show Strong Performance Of Veracyte’s Afirma Gsc In Real-World Clinical Practice
20 Jun 2022 //
PRESS RELEASE
Insider Buying: The Veracyte CEO & Director Just Bought 60% More Shares
15 Jun 2022 //
YAHOO FINANCE
Data Published In Annals Of Oncology Reinforce Clinical Utility Of Veracyte’
03 Jun 2022 //
PRESS RELEASE
Veracyte Announces New Data in 1L Treatment of Metastatic Colorectal Cancer
31 May 2022 //
BUSINESSWIRE
Veracyte Announces New Data to be Presented at ASCO 2022 in NSCLC
26 May 2022 //
BUSINESSWIRE
Veracyte Announces New Data Reinforcing Percepta Nasal
16 May 2022 //
PRESS RELEASE
Veracyte: Not A Healthy Diagnosis
12 May 2022 //
SEEKING ALPHA
Study validates Veracyte’s test for prostate cancer aggression
15 Feb 2022 //
FIERCEBIOTECH
New Data Validate Utility of Veracyte’s Decipher Prostate Genomic Classifier
14 Feb 2022 //
BUSINESSWIRE
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
08 Feb 2022 //
BUSINESSWIRE
Veracyte Says New Data to be Presented at the 2022 ASCO GU Cancers Symposium
31 Jan 2022 //
BUSINESSWIRE
Veracyte’s Percepta GSC Can Help Accelerate Treatment with Lung Cancer
24 Jan 2022 //
BUSINESSWIRE
Veracyte`s Data Demonstrates Clinical Utility of Envisia Genomic Classifier
14 Dec 2021 //
BUSINESSWIRE
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
13 Nov 2021 //
BUSINESSWIRE
Veracyte new Data Validate Prognostic Value of Decipher Prostate Genomic Test
25 Oct 2021 //
BUSINESSWIRE
Veracyte begins limited release of nasal swab lung cancer test
12 Oct 2021 //
FIERCEBIOTECH
New data confirms accuracy of Veracyte’s Envisia Genomic Classifier for IPF
11 Oct 2021 //
BUSINESSWIRE
New NCCN Guidelines Recommend Use of Decipher Prostate Genomic Test Score
14 Sep 2021 //
BUSINESSWIRE
Veracyte Announces Second Quarter 2021 Financial Results
29 Jul 2021 //
BUSINESSWIRE
Veracyte Announces Key Appointments to Executive Leadership Team
07 Jul 2021 //
BUSINESSWIRE
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
07 Jul 2021 //
BUSINESSWIRE
Veracyte Announces Two Pre-Eminent Physician Appointments
01 Jul 2021 //
BUSINESSWIRE
Veracyte prints new prostate cancer test data after Decipher buy
15 Jun 2021 //
FIERCE BIOTECH
JAMA Oncology Paper Shows Use of Veracyte’s Decipher Prostate Genomic Classifier
14 Jun 2021 //
BUSINESSWIRE
Veracyte lays out €260M for French cancer test maker HalioDx
02 Jun 2021 //
FIERCEBIOTECH
ASCO: Veracyte sets nasal swab lung cancer test for 2021 launch
19 May 2021 //
FIERCEBIOTECH
